

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

022405Orig1s000

PROPRIETARY NAME REVIEW(S)



**Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Surveillance and Epidemiology**

Date: March 21, 2011
Application Type/Number: NDA# 022405
Through: Todd Bridges, RPh, Team Leader
Carol Holquist, RPh, Director
Division of Medication Error Prevention and Analysis (DMEPA)
From: Denise V. Baugh, PharmD, BCPS, Safety Evaluator
Division of Medication Error Prevention and Analysis (DMEPA)
Subject: Proprietary Name Review
Drug Name(s): ^{(b) (4)} (Vandetanib) Tablets
100 mg and 300 mg
Applicant: AstraZeneca Pharmaceuticals, LP
OSE RCM #: 2011-224

***** Note: This review contains proprietary and confidential information that should not be released to the public.*****

30 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

DENISE V BAUGH
03/21/2011

TODD D BRIDGES
03/21/2011

CAROL A HOLQUIST
03/22/2011